Cyclic Oxidation-Reduction Reactions Regulate Thromboxane A2/Prostaglandin Hz Receptor Number and Affinity in Human Platelet Membranes*

نویسنده

  • Gerald W. Dorn
چکیده

The radiolabeled thromboxane As/prostaglandin HZ (TXAZ/PGHZ) agonist “‘1-BOP bound to the TXAs/ PGHZ receptor on human platelet membranes. Scatchard analysis showed that pretreatment of platelet membranes with the reducing agent dithiothreitol (DTT) (10 mM) for 10 min decreased maximal “‘IBOP binding (B,,,*J from 1.51 2 0.11 pmol/mg to 0.61 2 0.05 pmol/mg (p = 0.001) and increased the affinity of the remaining binding sites (Kd = 647 2 64 pM (untreated), 363 2 46 pM (treated), p = 0.006). Prolonged incubation of membranes with DTT (10 mM) for 40 min further reduced the B,,,** to 0.23 2 0.08 pmol/mg (p = 0.001 from untreated), and the binding affinity remained elevated (Kd = 334 2 117 pM, p = 0.035 from untreated). Kinetic analysis of 12’I-BOP binding indicated that the apparent increase in binding affinity after DTT treatment was due exclusively to an increase in the rate of ligand-receptor association with no change in dissociation rate. The effects of DTT on 12’I-BOP binding were dose-dependent with an EC&,, of 8.1 2 0.2 mM. DTT inactivation of TXA2/PGHZ receptors was time-dependent with a second order rate constant (&J of 0.123 Mm1 s-l at 20 ‘C. The platelet membrane 12’I-BOP binding site was partially protected from DTT inactivation by prior occupation with the ligand. TXA2/PGHZ receptor protection by I-BOP was dose-dependent and linearly related (r = 0.97, p = 0.002) to the proportion of receptors occupied, but was incomplete since agonist occupation of 89% of the total number of receptors resulted in only a 38% protective effect. Inhibition of “‘1-BOP binding after reduction with DTT could be made permanent by addition of the sulfhydryl alkylating agent N-ethylmaleimide (25 mM), but was completely reversed by reoxidation with dithionitrobenzoic acid (DTNB) (5 mM). Oxidation of untreated receptors with DTNB resulted in a 64% increase in 12’I-BOP binding sites from 1.65 2 0.12 pmol/mg to 2.70 2 0.08 pmol/mg (p = 0.013) without affecting binding affinity. DTNB-induced increases in 12’I-BOP binding were concentration-dependent with an ECbO of 668 2 106 PM and occurred in less than 1 min at 37 ‘C. In the absence of DTT, alkylation of free sulfhydryl groups with N-ethylmaleimide reduced “‘1-BOP Bmax in platelet membranes to 0.85 2 0.08 pmol/mg (p = 0.003), but did not change the affinity of the remaining

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Cyclic oxidation-reduction reactions regulate thromboxane A2/prostaglandin H2 receptor number and affinity in human platelet membranes.

The radiolabeled thromboxane A2/prostaglandin H2 (TXA2/PGH2) agonist 125I-BOP bound to the TXA2/PGH2 receptor on human platelet membranes. Scatchard analysis showed that pretreatment of platelet membranes with the reducing agent dithiothreitol (DTT) (10 mM) for 10 min decreased maximal 125I-BOP binding (Bmax) from 1.51 +/- 0.11 pmol/mg to 0.51 +/- 0.05 pmol/mg (p = 0.001) and increased the affi...

متن کامل

A role for prostaglandins and thromboxanes in the exposure of platelet fibrinogen receptors.

Exposure of fibrinogen receptors by a variety of agonists is a prerequisite for platelet aggregation. Because the synthesis of prostaglandins and thromboxane A2 also occurs during platelet aggregation we wondered whether these agents participate in the exposure of platelet fibrinogen receptors. Therefore, we measured the binding of human 125I-fibrinogen to gel-filtered normal human platelets af...

متن کامل

Characterization of the Vascular Thromboxane A2 /Prostaglandin Endoperoxide Receptor

Recently, we have shown that dexamethasone treatment of rabbits specifically reduces vascular smooth muscle responsiveness to agonists that interact with the vascular thromboxane A2 / prostaglandin H2 (TXA2 / PGH2) receptor. One potential site at which dexamethasone can influence prostanoid-mediated vasoconstriction may be at the level of the vascular TXA2 IPGH2 receptor. Therefore, we characte...

متن کامل

Cyclic adenosine 3',5'-monophosphate inhibits the availability of arachidonate to prostaglandin synthetase in human platelet suspensions.

When thrombin is added to washed human platelets, one of its actions results in activation of a phospholipase that hydrolyzes arachidonic acid from phospholipids. The arachidonate is converted to the cyclic endoperoxides (prostaglandin G2 and prostaglandin H2) by fatty acid cyclo-oxygenase. These compounds are then converted to thromboxane A2, also called rabbit aorta-contracting substance, by ...

متن کامل

Timosaponin AIII induces antiplatelet and antithrombotic activity via Gq-mediated signaling by the thromboxane A2 receptor

The thromboxane (Tx) A2 pathway is a major contributor to the amplification of initial platelet activation and is therefore a key drug target. To identify potent small-molecule inhibitors of the thromboxane prostaglandin (TP) receptor, we screened a small steroidal saponin library using U46619-induced rat platelet aggregation assays. Timosaponin AIII (TAIII) was identified as a potent inhibitor...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:

دوره   شماره 

صفحات  -

تاریخ انتشار 2001